Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HPD | P32754 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300573 | 0.87 | PTPN1 (0.40) | PTPN1TSHRUSP2ALDH1A1HSD17B10 | |
| SCHEMBL12284133 | 0.87 | FAAH (0.36) | TSHRLMNA | |
| SCHEMBL1300118 | 0.86 | PTPN1 (0.40) | PTPN1TSHRUSP2ALDH1A1HSD17B10 | |
| SCHEMBL1300319 | 0.85 | PTPN1 (0.40) | PTPN1TSHRUSP2ALDH1A1HSD17B10 | |
| SCHEMBL12108773 | 0.84 | PTPN1 (0.38) | PTPN1TSHRUSP2ALDH1A1HSD17B10 | |
| SCHEMBL1299606 | 0.83 | PTPN1 (0.38) | PTPN1TSHRUSP2ALDH1A1HSD17B10 | |
| SCHEMBL12109175 | 0.83 | PTPN1 (0.36) | PTPN1TSHRUSP2ALDH1A1HSD17B10 | |
| SCHEMBL1299093 | 0.82 | PTPN1 (0.36) | PTPN1ALDH1A1LMNAHPGDPDK1 | |
| SCHEMBL1299609 | 0.82 | CHRM2 (0.38) | PTPN1TSHRUSP2ALDH1A1HSD17B10 | |
| SCHEMBL12109182 | 0.81 | KDM4E (0.36) | PTPN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-04-20 | — | — | US | disclosed |
| EP-2552890-B1 | POLYCYCLIC TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-01-04 | — | — | EP | disclosed |
| US-9371283-B2 | Polycyclic tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| EP-2552890-A1 | POLYCYCLIC TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2011123536-A1 | POLYCYCLIC TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | PTPN1 470/4885TSHR 1136/4885USP2 4454/4885 |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | PTPN1 470/4885TSHR 1136/4885USP2 4454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.